OncLive® On Air
OncLive® On Air
In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.
Episodes
Mentioned books
Oct 19, 2023 • 16min
S9 Ep35: Hasanuma Highlights the Benefits of Building Authentic Connections Through Mentorship
Dr Hasunuma shares that the objective of mentorship is to foster care, trust, and respect in mentor-mentee relationships and create authentic connections.
Oct 16, 2023 • 12min
S9 Ep34: FDA Approval Insights: Momelotinib in Myelofibrosis With Anemia
Dr Kuykendall discusses the FDA approval of momelotinib in myelofibrosis with anemia, key data from the MOMENTUM trial, and how momelotinib alters the myelofibrosis treatment paradigm.
Oct 12, 2023 • 15min
S9 Ep33: Gutierrez and Leslie Discuss Recent Efforts and Future Advances in CAR T-Cell Therapy
Drs Gutierrez and Leslie discuss common barriers that institutions face when implementing CAR T-cell therapy programs, the early success story of outpatient administration of this modality at John Theurer Cancer Center, and future considerations for using this treatment approach in solid tumors.
Oct 9, 2023 • 15min
S9 Ep32: Expert Insights on the United States Chemotherapy Shortage
Oncology experts discuss the platinum chemotherapy shortage in the United States.
Oct 5, 2023 • 11min
S9 Ep31: FDA Approval Insights: First-Line Luspatercept for Anemia in Lower-Risk MDS
Dr Platzbecker discusses the FDA approval of luspatercept in lower-risk MDS with anemia; key efficacy and safety data from the COMMANDS trial; and how this approval addresses historically unmet needs for patients with MDS.
Oct 2, 2023 • 25min
S9 Ep30: Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma
Dr Richardson discusses the background of mezigdomide, key efficacy and safety findings with the agent plus dexamethasone in patients with relapsed/refractory multiple myeloma, and the implications of this combination for heavily pretreated patients in this population.
Sep 28, 2023 • 30min
S9 Ep29: Garcia-Manero and Zeidan Highlight Key Implications of the COMMANDS Trial in Lower-Risk MDS
Drs Garcia-Manero and Zeidan discuss the significance of efficacy and safety data from the COMMANDS trial in MDS, takeaways from the subgroup analyses, and expectations around treatment sequencing in the lower-risk MDS population.
Sep 21, 2023 • 19min
S9 Ep28: FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma
Dr Nooka discusses the FDA approval of elranatamab in relapsed/refractory multiple myeloma, key data from MagnetisMM-3, and the evolving role of bispecific antibodies in the multiple myeloma treatment paradigm.
Sep 18, 2023 • 22min
S9 Ep27: Jones and Somaiah Review the Rationale and Design of the Peak Trial in GIST
Drs Jones and Somaiah discuss unmet needs in GIST that the Peak trial seeks to answer; the advantages of the methods and design of this trial; and how the tolerable safety profile of bezuclastinib plus sunitinib supports further research with this combination.
Sep 14, 2023 • 16min
S9 Ep26: Chuong Discusses the Importance of MRI-Guided Radiotherapy in Cancer
Dr Chuong discusses the evolution of MRI-guided radiation in the cancer treatment armamentarium, the benefits of the MRIdian SMART system, and how Miami Cancer Institute is leading the way with trainings to expand the use of this technology.
